Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
104,661,494
-
Total 13F shares
-
81,380,096
-
Share change
-
-1,516,185
-
Total reported value
-
$209,199,026
-
Put/Call ratio
-
35%
-
Price per share
-
$2.57
-
Number of holders
-
172
-
Value change
-
-$16,428,979
-
Number of buys
-
85
-
Number of sells
-
79
Institutional Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q2 2024
As of 30 Jun 2024,
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) was held by
172 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
81,380,096 shares.
The largest 10 holders included
Capital World Investors, BlackRock Inc., FRANKLIN RESOURCES INC, VANGUARD GROUP INC, Palo Alto Investors LP, Polar Capital Holdings Plc, JPMORGAN CHASE & CO, Stonepine Capital Management, LLC, Rubric Capital Management LP, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
168
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.